Article Sidebar

pdf
Date Published: 21/04/2025
Abstract Views: 189
Views pdf: 112
DOI: https://doi.org/10.51298/vmj.v549i1.13500
Issue
Vol. 549 No. 1 (2025)
Section
Các bài báo
How to Cite
Đào Việt, H., Trần Thị Thu, T., & Phạm Thanh, V. (2025). CLINICAL OUTCOMES OF HELICOBACTER PYLORI ERADICATION THERAPY COMBINED WITH PROBIOTIC ECOLOGIC AAD IN PATIENTS WITH PEPTIC ULCER DISEASE. Vietnam Medical Journal, 549(1). https://doi.org/10.51298/vmj.v549i1.13500

CLINICAL OUTCOMES OF HELICOBACTER PYLORI ERADICATION THERAPY COMBINED WITH PROBIOTIC ECOLOGIC AAD IN PATIENTS WITH PEPTIC ULCER DISEASE

Hằng Đào Việt, Trang Trần Thị Thu, Vân Phạm Thanh

Main Article Content

Abstract

A prospective cohort study conducted at Hoang Long Clinic and the Institute of Gastroenterology and Hepatology from December 2023 to January 2024 on 100 H. pylori-infected patients treated with a H. pylori eradication regimen supplemented with Ecologic AAD. Patients were follow-up at 2 weeks (82 patients), 4 weeks (82 patients) and 8 weeks (58 patients) post-enrollment to assess clinical symptom improvement and medication adherence. The majority of subjects were female (64%) and the mean age is 45.7 ± 14.2. Upper gastrointestinal, lower gastrointestinal, and alarming symptoms recorded at the time of enrollment significantly decreased by week 2 and were nearly absent by weeks 4 and 8. The adherence rate to the treatment regimen was 92.3%. 20.7% of patients reported experiencing adverse events during the treatment, mainly diarrhea, fatigue, and abdominal pain. 35 patients had post-treatment breath test results with a successful eradication rate of 94,3%. More clinical trials are needed to provide evidence on the efficacy of the H. pylori treatment regimen supplemented with probiotics.

Article Details

Keywords

Helicobacter pylori, probiotic, medication adherence, successful eradication

References

1. Quach, D.T., et al., Vietnam Association of Gastroenterology (VNAGE) consensus on the management of Helicobacter pylori infection. Front Med (Lausanne), 2022. 9: p. 1065045.
2. Chey, W.D., et al., ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Official journal of the American College of Gastroenterology | ACG, 2024. 119(9).
3. Organisation, W.G., Probiotics and Prebiotics. 2023.
4. Malfertheiner, P., et al., Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut, 2022.
5. World Gastroenterology Organisation Global Guidelines, Probiotics and prebiotics. 2023.
6. Poonyam, P., P. Chotivitayatarakorn, and R.K. Vilaichone, High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev, 2019. 20(9): p. 2859-2864.
7. Nyssen, O.P., et al., Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol, 2021. 116(6): p. 1220-1229.
8. Yao, G., X. Fan, and D. Lu, Efficacy and safety of probiotic-supplemented bismuth quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review and meta-analysis. J Int Med Res, 2023. 51(10): p. 3000605231203841.
9. Hoàng, H. and Đ.S.J.T.c.Y.h.V.N. Trần, tuân thủ điều trị tiệt trừ helicobacter pylori và các yếu tố liên quan ở bệnh nhân điều trị ngoại trú tại bệnh viện quận 2, tp. hcm. 2021. 500(1).
10. Huy, T.V.J.T.c.Y.D.h.-T.Đ.h.Y.D.H., Nghiên cứu kết quả điều trị tiệt trừ Helicobacter pylori bằng phác đồ bốn thuốc có Bismuth cải tiến RBMA 14 ngày ở bệnh nhân viêm dạ dày mạn. 2019. 9(2): p. 28-32.